Radhe Mohan1, Amy Y Liu1, Paul D Brown2, Anita Mahajan2, Jeffrey Dinh3, Caroline Chung4, Sarah McAvoy5, Mary Frances McAleer4, Steven H Lin4, Jing Li4, Amol J Ghia4, Cong Zhu1,6, Erik P Sulman7, John F de Groot8, Amy B Heimberger9, Susan L McGovern4, Clemens Grassberger10, Helen Shih10, Susannah Ellsworth11, David R Grosshans4. 1. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Radiation Oncology, Mayo Clinic Hospital, Rochester, Minnesota. 3. Millennium Physicians Radiation Oncology, The Woodlands, Texas. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Radiation Oncology, University of Maryland, Baltimore, Maryland. 6. Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, The University of Texas Health Science Center, Houston, Texas. 7. Department of Radiation Oncology, NYU Grossman School of Medicine, New York, New York. 8. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 9. Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 10. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts. 11. Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indiana.
Abstract
BACKGROUND: We investigated differences in radiation-induced grade 3+ lymphopenia (G3+L), defined as an absolute lymphocyte count (ALC) nadir of <500 cells/µL, after proton therapy (PT) or X-ray (photon) therapy (XRT) for patients with glioblastoma (GBM). METHODS: Patients enrolled in a randomized phase II trial received PT (n = 28) or XRT (n = 56) concomitantly with temozolomide. ALC was measured before, weekly during, and within 1 month after radiotherapy. Whole-brain mean dose (WBMD) and brain dose-volume indices were extracted from planned dose distributions. Univariate and multivariate logistic regression analyses were used to identify independent predictive variables. The resulting model was evaluated using receiver operating characteristic (ROC) curve analysis. RESULTS:Rates of G3+L were lower in men (7/47 [15%]) versus women (19/37 [51%]) (P < 0.001), and for PT (4/28 [14%]) versus XRT (22/56 [39%]) (P = 0.024). G3+L was significantly associated with baseline ALC, WBMD, and brain volumes receiving 5‒40 Gy(relative biological effectiveness [RBE]) or higher (ie, V5 through V40). Stepwise multivariate logistic regression analysis identified being female (odds ratio [OR] 6.2, 95% confidence interval [CI]: 1.95‒22.4, P = 0.003), baseline ALC (OR 0.18, 95% CI: 0.05‒0.51, P = 0.003), and whole-brain V20 (OR 1.07, 95% CI: 1.03‒1.13, P = 0.002) as the strongest predictors. ROC analysis yielded an area under the curve of 0.86 (95% CI: 0.79-0.94) for the final G3+L prediction model. CONCLUSIONS: Sex, baseline ALC, and whole-brain V20 were the strongest predictors of G3+L for patients with GBM treated with radiation and temozolomide. PT reduced brain volumes receiving low and intermediate doses and, consequently, reduced G3+L.
RCT Entities:
BACKGROUND: We investigated differences in radiation-induced grade 3+ lymphopenia (G3+L), defined as an absolute lymphocyte count (ALC) nadir of <500 cells/µL, after proton therapy (PT) or X-ray (photon) therapy (XRT) for patients with glioblastoma (GBM). METHODS:Patients enrolled in a randomized phase II trial received PT (n = 28) or XRT (n = 56) concomitantly with temozolomide. ALC was measured before, weekly during, and within 1 month after radiotherapy. Whole-brain mean dose (WBMD) and brain dose-volume indices were extracted from planned dose distributions. Univariate and multivariate logistic regression analyses were used to identify independent predictive variables. The resulting model was evaluated using receiver operating characteristic (ROC) curve analysis. RESULTS: Rates of G3+L were lower in men (7/47 [15%]) versus women (19/37 [51%]) (P < 0.001), and for PT (4/28 [14%]) versus XRT (22/56 [39%]) (P = 0.024). G3+L was significantly associated with baseline ALC, WBMD, and brain volumes receiving 5‒40 Gy(relative biological effectiveness [RBE]) or higher (ie, V5 through V40). Stepwise multivariate logistic regression analysis identified being female (odds ratio [OR] 6.2, 95% confidence interval [CI]: 1.95‒22.4, P = 0.003), baseline ALC (OR 0.18, 95% CI: 0.05‒0.51, P = 0.003), and whole-brain V20 (OR 1.07, 95% CI: 1.03‒1.13, P = 0.002) as the strongest predictors. ROC analysis yielded an area under the curve of 0.86 (95% CI: 0.79-0.94) for the final G3+L prediction model. CONCLUSIONS: Sex, baseline ALC, and whole-brain V20 were the strongest predictors of G3+L for patients with GBM treated with radiation and temozolomide. PT reduced brain volumes receiving low and intermediate doses and, consequently, reduced G3+L.
Authors: Rajayogesh Davuluri; Wen Jiang; Penny Fang; Cai Xu; Ritsuko Komaki; Daniel R Gomez; James Welsh; James D Cox; Christopher H Crane; Charles C Hsu; Steven H Lin Journal: Int J Radiat Oncol Biol Phys Date: 2017-06-01 Impact factor: 7.038
Authors: Yutaka Shiraishi; Penny Fang; Cai Xu; Juhee Song; Sunil Krishnan; Eugene J Koay; Reza J Mehran; Wayne L Hofstetter; Mariela Blum-Murphy; Jaffer A Ajani; Ritsuko Komaki; Bruce Minsky; Radhe Mohan; Charles C Hsu; Brian P Hobbs; Steven H Lin Journal: Radiother Oncol Date: 2017-12-14 Impact factor: 6.280
Authors: Martina Absinta; Seung-Kwon Ha; Govind Nair; Pascal Sati; Nicholas J Luciano; Maryknoll Palisoc; Antoine Louveau; Kareem A Zaghloul; Stefania Pittaluga; Jonathan Kipnis; Daniel S Reich Journal: Elife Date: 2017-10-03 Impact factor: 8.140
Authors: Robert H Press; Arpit M Chhabra; J Isabelle Choi; Shaakir Hasan; Madhur Garg; Sonam Sharma; Stanislav Lazarev; T Jonathan Yang; Josh Yamada; Charles B Simone Journal: Neuro Oncol Date: 2021-11-02 Impact factor: 13.029
Authors: Arnold Pompos; Robert L Foote; Albert C Koong; Quynh Thu Le; Radhe Mohan; Harald Paganetti; Hak Choy Journal: Front Oncol Date: 2022-06-14 Impact factor: 5.738
Authors: Jonathan Khalifa; Julien Mazieres; Carlos Gomez-Roca; Maha Ayyoub; Elizabeth Cohen-Jonathan Moyal Journal: Front Oncol Date: 2021-04-21 Impact factor: 6.244
Authors: Valentina Bravatà; Walter Tinganelli; Francesco P Cammarata; Luigi Minafra; Marco Calvaruso; Olga Sokol; Giada Petringa; Giuseppe A P Cirrone; Emanuele Scifoni; Giusi I Forte; Giorgio Russo Journal: J Pers Med Date: 2021-04-16
Authors: Lieke In 't Ven; Erik Roelofs; Macarena Cubillos Mesías; Inge Compter; Yvonne L B Klaver; Robert Jan Smeenk; Geert O Janssens; Johannes H A M Kaanders; Raquel Davila Fajardo; Foppe Oldenburger; Dirk de Ruysscher; Esther G C Troost; Daniëlle B P Eekers Journal: Clin Transl Radiat Oncol Date: 2021-02-22
Authors: Hwa Kyung Byun; Min Cheol Han; Kyungmi Yang; Jin Sung Kim; Gyu Sang Yoo; Woong Sub Koom; Yong Bae Kim Journal: Cancer Res Treat Date: 2021-06-16 Impact factor: 4.679